Takeda’s Mezagitamab Delivers Sustained Platelet Boost In Phase 2 Clinical Trials For Treatment of Immune Thrombocytopenia Purpura
- Mezagitamab achieved a sustained platelet response and symptomatic relief in patients treated for chronic ITP.
- Mezagitamab showed a favorable safety profile and was well tolerated by patients.
The Latest
In a double-blind, randomized, phase 2b clinical trial funded by Takeda, researchers investigated the safety and efficacy of Mezagitamab for the treatment of chronic immune thrombocytopenia (ITP). Patients were separated into three dose groups and given subcutaneous Mezagitamab once weekly for eight weeks. Patients in the 600 mg dose level achieved the most meaningful results: 81.8% experienced a complete platelet response, 90.9% found clinically meaningful improvement, and 100% achieved a hemostatic response. The safety profile of Mezagitamab remains consistent with previous studies and was well tolerated by patients in this trial. Takeda plans to advance Mezagitamab into phase 3 trials later this year.
Physician’s Perspective
ITP is defined by a decreased platelet count—a type of blood cell in the body responsible for forming clots and preventing further bleeding. The cause of primary ITP is unknown. In ITP, the body produces IgG antibodies against platelets which eventually become trapped and broken down in the liver and spleen. ITP is typically asymptomatic but can present with signs of superficial bleeding, bruising, and in severe cases life-threatening bleeding. Treatment varies based on symptom severity. Asymptomatic patients are treated with supportive care, while those with more severe symptoms are treated with corticosteroids and/or intravenous immunoglobulin therapy. These treatment options aim to reduce the body’s immune response and ultimately increase platelets. With evidence of fast and sustained elevation in platelet counts, Takeda’s Mezagitamab has shown to be a promising ITP treatment option in the future.
Molecular Target of Therapy
Mezagitamab is a monoclonal antibody that acts against and depletes CD38-expressing cells. Plasma cells and plasmablasts are two important CD38-expressing cells that secrete IgG antibodies targeted against platelets. By depleting these cells, Mezagitamab reduces autoantibody attacks against platelets, thereby increasing platelet counts to treat ITP.
Company History
Takeda is a pharmaceutical company based in Japan. Takeda’s areas of focus include neurological diseases, gastrointestinal diseases, cancer, and more. Recently, Takeda’s maribavir received approval for treatment of post-transplant CMV infection in more than 30 countries.
Further reading: https://www.takeda.com/newsroom/newsreleases/2024/late-breaking-data-from-phase-2b-study-of-mezagitamab/
©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
